GlassScriptPhysician profile
Leslie B Aden
NPI 1700805363
$37,835.92
in general payments reported to CMS, 2019-2025
22 companies · $9,869 in 2025
The $9,869 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $1,670 · 2021: $5,333 · 2022: $1,902 · 2023: $3,946 · 2024: $3,880 · 2025: $9,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $6,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,385.00 |
| Food and Beverage | $6,310.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $32,583.93 | 2019-2025 | Lensx, Ora System Verifeye, Clareon |
| Glaukos Corporation | $3,065.30 | 2019-2025 | Istent Infinite, Idosetr |
| Bausch & Lomb Americas INC. | $503.49 | 2022-2024 | Vyzulta, Miebo, Lotemax Sm |
| Abbvie INC. | $352.81 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Oyster Point Pharma, INC. | $207.10 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $199.74 | 2019-2021 | |
| New World Medical,INC. | $164.65 | 2022 | |
| Allergan, INC. | $132.82 | 2019-2022 | |
| Thea Pharma INC. | $98.81 | 2023-2025 | Iyuzeh |
| Mallinckrodt Hospital Products INC. | $97.45 | 2025 | Acthar |
| Aerie Pharmaceuticals, INC. | $84.11 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $71.52 | 2020-2022 | |
| Biotissue Holdings INC. | $53.45 | 2022-2025 | |
| Ocular Therapeutix, INC. | $44.88 | 2022-2024 | Dextenza |
| Kala Pharmaceuticals, INC. | $40.08 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $29.55 | 2019 | |
| Eyepoint US, INC. | $20.04 | 2019 | |
| Sight Sciences, INC. | $18.44 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Horizon Therapeutics Plc | $18.08 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $17.31 | 2022 | |
| Eyevance Pharmaceuticals LLC | $16.31 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $16.05 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Aden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.